|
1
|
Chou CH, Chou YE, Chuang CY, Yang SF and
Lin CW: Combined effect of genetic polymorphisms of AURKA and
environmental factors on oral cancer development in Taiwan. PLoS
One. 12:e01715832017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reyes-Gibby CC, Anderson KO, Merriman KW,
Todd KH, Shete SS and Hanna EY: Survival patterns in squamous cell
carcinoma of the head and neck: Pain as an independent prognostic
factor for survival. J Pain. 15:1015–1022. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee WH, Chen HM, Yang SF, Liang C, Peng
CY, Lin FM, Tsai LL, Wu BC, Hsin CH, Chuang CY, et al: Bacterial
alterations in salivary microbiota and their association in oral
cancer. Sci Rep. 7:165402017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dave K, Ali A and Magalhaes M: Increased
expression of PD-1 and PD-L1 in oral lesions progressing to oral
squamous cell carcinoma: A pilot study. Sci Rep. 10:97052020.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haddad RI and Shin DM: Recent advances in
head and neck cancer. N Engl J Med. 359:1143–1154. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tremblay M, Sanchez-Ferras O and Bouchard
M: GATA transcription factors in development and disease.
Development. 145:dev1643842018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Jiang X, Li D, Shen W, Shen X and Liu Y:
LncRNA NEAT1 promotes hypoxia-induced renal tubular epithelial
apoptosis through downregulating miR-27a-3p. J Cell Biochem.
120:16273–16282. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Martinelli P, Carrillo-de Santa Pau E, Cox
T, Sainz B Jr, Dusetti N, Greenhalf W, Rinaldi L, Costello E,
Ghaneh P, Malats N, et al: GATA6 regulates EMT and tumour
dissemination, and is a marker of response to adjuvant chemotherapy
in pancreatic cancer. Gut. 66:1665–1676. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Deng X, Jiang P, Chen J, Li J, Li D, He Y,
Jiang Y, Zhang Y, Xu S, Li X, et al: GATA6 promotes
epithelial-mesenchymal transition and metastasis through
MUC1/β-catenin pathway in cholangiocarcinoma. Cell Death Dis.
11:8602020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sulahian R, Casey F, Shen J, Qian ZR, Shin
H, Ogino S, Weir BA, Vazquez F, Liu XS, Hahn WC, et al: An
integrative analysis reveals functional targets of GATA6
transcriptional regulation in gastric cancer. Oncogene.
33:5637–5648. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Tsuji S, Kawasaki Y, Furukawa S, Taniue K,
Hayashi T, Okuno M, Hiyoshi M, Kitayama J and Akiyama T: The
miR-363-GATA6-Lgr5 pathway is critical for colorectal
tumourigenesis. Nat Commun. 5:31502014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xu CL, Guan WQ and Wang XY: The expression
of the GATA6 gene in oral carcinoma cell lines. World J Surg Oncol.
19:1532021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Deng L and Liu H: MicroRNA-506 suppresses
growth and metastasis of oral squamous cell carcinoma via targeting
GATA6. Int J Clin Exp Med. 8:1862–1870. 2015.PubMed/NCBI
|
|
14
|
Gao W, Liu Y, Qin R, Liu D and Feng Q:
Silence of fibronectin 1 increases cisplatin sensitivity of
non-small cell lung cancer cell line. Biochem Biophys Res Commun.
476:35–41. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yen CY, Huang CY, Hou MF, Yang YH, Chang
CH, Huang HW, Chen CH and Chang HW: Evaluating the performance of
fibronectin 1 (FN1), integrin α4β1 (ITGA4), syndecan-2 (SDC2), and
glycoprotein CD44 as the potential biomarkers of oral squamous cell
carcinoma (OSCC). Biomarkers. 18:63–72. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen Z, Tao Q, Qiao B and Zhang L:
Silencing of LINC01116 suppresses the development of oral squamous
cell carcinoma by up-regulating microRNA-136 to inhibit FN1. Cancer
Manag Res. 11:6043–6059. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartha Á and Győrffy B: TNMplot.com: A web
tool for the comparison of gene expression in normal, tumor and
metastatic tissues. Int J Mol Sci. 22:26222021. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vasaikar SV, Straub P, Wang J and Zhang B:
LinkedOmics: Analyzing multi-omics data within and across 32 cancer
types. Nucleic Acids Res. 46:D956–D963. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Allison TF, Smith AJH, Anastassiadis K,
Sloane-Stanley J, Biga V, Stavish D, Hackland J, Sabri S, Langerman
J, Jones M, et al: Identification and single-cell functional
characterization of an endodermally biased pluripotent substate in
human embryonic stem cells. Stem Cell Reports. 10:1895–1907. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang G, Meng W, Huang X, Zhu W, Yin C,
Wang C, Fassan M, Yu Y, Kudo M, Xiao S, et al: miR-196b-5p-mediated
downregulation of TSPAN12 and GATA6 promotes tumor progression in
non-small cell lung cancer. Proc Natl Acad Sci USA. 117:4347–4357.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tan HW, Leung CO, Chan KK, Ho DW, Leung
MS, Wong CM, Ng IO and Lo RC: Deregulated GATA6 modulates stem
cell-like properties and metabolic phenotype in hepatocellular
carcinoma. Int J Cancer. 145:1860–1873. 2019.PubMed/NCBI
|
|
23
|
Wang C, Liu Q, Huang M, Zhou Q, Zhang X,
Zhang J, Xie R, Yu Y, Chen S, Fan J, et al: Loss of GATA6
expression promotes lymphatic metastasis in bladder cancer. FASEB
J. 34:5754–5766. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cheung WK, Zhao M, Liu Z, Stevens LE, Cao
PD, Fang JE, Westbrook TF and Nguyen DX: Control of alveolar
differentiation by the lineage transcription factors GATA6 and HOPX
inhibits lung adenocarcinoma metastasis. Cancer Cell. 23:725–738.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fang P, Shi HY, Wu XM, Zhang YH, Zhong YJ,
Deng WJ, Zhang YP and Xie M: Targeted inhibition of GATA-6
attenuates airway inflammation and remodeling by regulating
caveolin-1 through TLR2/MyD88/NF-κB in murine model of asthma. Mol
Immunol. 75:144–150. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ding Y, Pan Y, Liu S, Jiang F and Jiao J:
Elevation of MiR-9-3p suppresses the epithelial-mesenchymal
transition of nasopharyngeal carcinoma cells via down-regulating
FN1, ITGB1 and ITGAV. Cancer Biol Ther. 18:414–424. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Steffens S, Schrader AJ, Vetter G, Eggers
H, Blasig H, Becker J, Kuczyk MA and Serth J: Fibronectin 1 protein
expression in clear cell renal cell carcinoma. Oncol Lett.
3:787–790. 2012.PubMed/NCBI
|
|
28
|
Wu J, Wang Y, Xu X, Cao H, Sahengbieke S,
Sheng H, Huang Q and Lai M: Transcriptional activation of FN1 and
IL11 by HMGA2 promotes the malignant behavior of colorectal cancer.
Carcinogenesis. 37:511–521. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Shi H, Dong Z and Gao H: LncRNA TUG1
protects against cardiomyocyte ischaemia reperfusion injury by
inhibiting HMGB1. Artif Cells Nanomed Biotechnol. 47:3511–3516.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Cai X, Liu C, Zhang TN, Zhu YW, Dong X and
Xue P: Down-regulation of FN1 inhibits colorectal carcinogenesis by
suppressing proliferation, migration, and invasion. J Cell Biochem.
119:4717–4728. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xie Y, Liu C, Qin Y, Chen J and Fang J:
Knockdown of IRE1a suppresses metastatic potential of colon cancer
cells through inhibiting FN1-Src/FAK-GTPases signaling. Int J
Biochem Cell Biol. 114:1055722019. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song G, Liu K, Yang X, Mu B, Yang J, He L,
Hu X, Li Q, Zhao Y, Cai X, et al: SATB1 plays an oncogenic role in
esophageal cancer by up-regulation of FN1 and PDGFRB. Oncotarget.
8:17771–17784. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu X, Liu Z, Zhou L, Xie H, Cheng J, Ling
Q, Wang J, Guo H, Wei X and Zheng S: Characterization of
genome-wide TFCP2 targets in hepatocellular carcinoma: Implication
of targets FN1 and TJP1 in metastasis. J Exp Clin Cancer Res.
34:62015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun Y, Zhao C, Ye Y, Wang Z, He Y, Li Y
and Mao H: High expression of fibronectin 1 indicates poor
prognosis in gastric cancer. Oncol Lett. 19:93–102. 2020.PubMed/NCBI
|
|
35
|
Han S, Khuri FR and Roman J: Fibronectin
stimulates non-small cell lung carcinoma cell growth through
activation of Akt/mammalian target of rapamycin/S6 kinase and
inactivation of LKB1/AMP-activated protein kinase signal pathways.
Cancer Res. 66:315–323. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhan S, Li J, Wang T and Ge W:
Quantitative proteomics analysis of sporadic medullary thyroid
cancer reveals FN1 as a potential novel candidate prognostic
biomarker. Oncologist. 23:1415–1425. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ji J, Chen L, Zhuang Y, Han Y, Tang W and
Xia F: Fibronectin 1 inhibits the apoptosis of human trophoblasts
by activating the PI3K/Akt signaling pathway. Int J Mol Med.
46:1908–1922. 2020.PubMed/NCBI
|
